# Roadmap 2.0: A randomized controlled trial using a technology-mediated platform in family caregivers of BMT patients

> **NIH NIH R01** · UNIVERSITY OF MICHIGAN AT ANN ARBOR · 2021 · $351,000

## Abstract

ABSTRACT
For decades, the nation’s rapidly aging population and rising need for family caregivers have been called to
attention. Indeed, with earlier hospital discharges, the demands placed on caregivers continue to intensify. This
is perhaps most pronounced in caregivers of patients undergoing allogeneic hematopoietic cell transplantation.
Over the last three decades, caregiver interventions have been shown to be effective in improving caregiver
well-being. However, most of them have focused on the negative aspects of caregiving (e.g., burden) with very
few focused on the positive aspects of caregiving (e.g., benefit). Further, outcomes have traditionally relied on
long-term recall and snapshot self-report. Thus, there has been limited understanding of the mechanism of action
of an intervention. Mobile health technology has been shown to deliver flexible and time- and cost-sparing
interventions to support caregivers across the care trajectory and enable the collection of continuous, multi-
parameter physiological data. These highly time-resolved parameters correlated with snapshot self-report data
have potential to provide new mechanistic insights of an intervention. The objective of this proposal is to leverage
technology to deliver a novel caregiver-facing mobile health intervention guided by a conceptual framework of
Carbonneau’s positive aspects of caregiving. Our interdisciplinary team will take our recent success of
developing a multi-component, caregiver-facing mobile health product (BMT Roadmap) and further expand and
test the intervention (Roadmap 2.0) in a randomized controlled trial. Our central hypothesis is that a multi-
component technology-mediated intervention with focus on the positive aspects of caregiving will improve
caregiver well-being. The study will be conducted in two phases. During Phase 1, we will identify positive
constructs that reflect that caregiving process among diverse stakeholders, expand the system with new
components, and pilot test Roadmap 2.0 through an iterative user-centered design process. Phase 2 will involve
a two-arm study design where participants will be randomized to a treatment arm (mobile platform + Roadmap
2.0) or to a control arm (mobile platform + usual care) following a baseline assessment. The duration of the study
will involve an active ~18-week intervention phase. We will recruit and randomize ~166 caregivers and patients
(332 total). Participants will be assessed at baseline, day 30, and day 120 post-transplant. The primary outcome
measure will be caregiver PROMIS Global Health at day 120. Secondary measures will include indices assessing
positive aspects of well-being (e.g., self-efficacy, positive affect) and negative aspects of well-being (e.g.,
depression, anxiety, sleep disturbance). We will conduct a rigorous mixed methods process evaluation to
determine the active and less active components of the system on caregiver and patient outcomes. We will also
employ a novel data-driven app...

## Key facts

- **NIH application ID:** 10183309
- **Project number:** 5R01HL146354-03
- **Recipient organization:** UNIVERSITY OF MICHIGAN AT ANN ARBOR
- **Principal Investigator:** SUNG WON CHOI
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $351,000
- **Award type:** 5
- **Project period:** 2019-04-01 → 2024-03-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10183309

## Citation

> US National Institutes of Health, RePORTER application 10183309, Roadmap 2.0: A randomized controlled trial using a technology-mediated platform in family caregivers of BMT patients (5R01HL146354-03). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10183309. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*